GTC Biotherapeutics (fka GTCB)

[ThomasS]

4 IND's: FVIIa, FIX, rhAAT, CD137.
Methinks we should be expecting a partner to formally sign up for CD137 and rhAAT (LFB or not) by YE 2008.

I can't help but believe that there will be other mab's headed GTC's way for production during the course of 2008/09. There is significant lead time involved for development/production in advance of both a) clinical development of new mab's, and b) in advance of existing patent expirations for existing mab's such as is the case for Rituxan/CD20. (What more proof do the detractors need than CD20?)
We accelerate from here, imo. Not necessarily share price, but definetly pace of activity in Massachusetts.